Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  2014-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD005590.PUB3PMID 17636808
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective

  2009cited by this paper
• Outbreak of Pneumocystis jiroveci Pneumonia in Renal Transplant Recipients: P. jiroveci Is Contagious to the Susceptible Host

  2009cited by this paper
• Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials.

  2007cited by this paper
• Placebo

  2007cited by this paper
• Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study

  2005cited by this paper
• An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital

  2005cited by this paper
• Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial.

  2004cited by this paper
• Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: A strategy for prevention

  2004cited by this paper
• Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda.

  2004cited by this paper
• Prevention of Infection Due to Pneumocystis spp. in Human Immunodeficiency Virus-Negative Immunocompromised Patients

  2004cited by this paper
• Sulfa Use, Dihydropteroate Synthase Mutations, and Pneumocystis jirovecii Pneumonia

  2004cited by this paper
• Dihydropteroate Synthase Gene Mutations in Pneumocystis and Sulfa Resistance

  2004cited by this paper
• Food and Drug Administration Center for Biologics Evaluation and Research

  2003cited by this paper
• Fungal Infections in Solid Organ Transplant Patients

  2003cited by this paper
• Infectious complications in patients randomized to receive allogeneic bone marrow or peripheral blood transplantation

  2003cited by this paper
• Infections and anti-tumor necrosis factor alpha therapy.

  2003cited by this paper
• Cotrimoxazole prophylaxis for opportunistic infections in adults with HIV.

  2003cited by this paper
• Cotrimoxazole prophylaxis for opportunistic infections in children with HIV infection.

  2003cited by this paper
• Infections and anti–tumor necrosis factor α therapy

  2003cited by this paper
• A New Name for Pneumocystis from Humans and New Perspectives on the Host-Pathogen Relationship

  2002cited by this paper
• Analysis of Underlying Diseases and Prognosis Factors Associated with Pneumocystis carinii Pneumonia in Immunocompromised HIV-Negative Patients

  2002cited by this paper
• Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome.

  2002cited by this paper
• Fungal infection in lung transplantation.

  2002cited by this paper
• [Guidelines for Prevention of Pneumocystis carinii Pneumonitis in Children and Adolescents with Cancer].

  2001cited by this paper
• Empfehlungen zur Prävention der Pneumocystis-carinii-Pneumonie bei Kindern und Jugendlichen mit neoplastischen Erkrankungen

  2001cited by this paper
• Pneumocystis carinii Pneumonia prophylaxis with atovaquone in trimethoprim‐sulfamethoxazole–intolerant orthotopic liver transplant patients: A preliminary study

  2001cited by this paper
• Infectious complications of lung transplantation

  2001cited by this paper
• Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P carinii pneumonia in patients with HIV-1: a prospective study.

  2001cited by this paper
• Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants.

  2001cited by this paper
• Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections.

  2000cited by this paper
• Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states.

  2000cited by this paper
• Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients.

  2000cited by this paper
• Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy.

  2000cited by this paper
• Randomized trial of weekly sulfadoxine/pyrimethamine vs. daily low-dose trimethoprim-sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation.

  1999cited by this paper
• Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia.

  1999cited by this paper
• High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis.

  1999cited by this paper
• Efficacy of sulfamethoxazole-trimethoprim administration in the prevention of Pneumocystis carinii pneumonia in patients with connective tissue disease.

  1999cited by this paper
• A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation

  1999cited by this paper
• Pneumocystis carinii pneumonia in patients receiving immunosuppressive drugs for dermatological diseases

  1999cited by this paper
• Prevention of infectious complications in rheumatic disease patients: immunization, Pneumocystis carinii prophylaxis, and screening for latent infections.

  1999cited by this paper
• Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis.

  1998cited by this paper
• The cost-effectiveness of preventing AIDS-related opportunistic infections.

  1998cited by this paper
• Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

  1998cited by this paper
• Infections in solid-organ transplant recipients

  1997cited by this paper
• Antimicrobial prophylaxis to prevent opportunistic infections in patients with chronic lymphocytic leukemia after allogeneic blood or marrow transplantation.

  1997cited by this paper
• Bias in meta-analysis detected by a simple, graphical test

  1997cited by this paper
• Pneumocystis carinii pneumonia in infants after heart transplantation.

  1996cited by this paper
• Prophylactic antibiotics for the prevention of early infection in multiple myeloma.

  1996cited by this paper
• Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group.

  1996cited by this paper
• Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis

  1996cited by this paper
• Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy.

  1996cited by this paper
• Effectiveness of daily low-dose cotrimoxazole prophylaxis for Pneumocystis carinii pneumonia in liver transplantation--an open clinical trial.

  1996cited by this paper
• Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients.

  1996cited by this paper
• Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials.

  1995cited by this paper
• The tolerance for zidovudine plus thrice weekly or daily trimethoprim-sulfamethoxazole with and without leucovorin for primary prophylaxis in advanced HIV disease. California Collaborative Treatment Group.

  1995cited by this paper
• Successful Pneumocystis carinii pneumonia prophylaxis using aerosolized pentamidine in children with acute leukemia.

  1994cited by this paper
• Adjunctive folinic acid with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death.

  1994cited by this paper
• Aerosolized pentamidine for the prevention of Pneumocystis carinii pneumonia in children with cancer intolerant or allergic to trimethoprim/sulfamethoxazole.

  1994cited by this paper
• Pneumocystis carinii pneumonia in patients without AIDS.

  1993cited by this paper
• Systemic Pneumocystis carinii pneumonia prophylaxis with dapsone and pyrimethamine fails to protect against extrapulmonary pneumocystosis.

  1993cited by this paper
• A randomized comparison of once-monthly or twice-monthly high-dose aerosolized pentamidine prophylaxis.

  1993cited by this paper
• Trimethoprim-sulfamethoxazole prophylaxis in granulocytopenic patients with acute leukemia: evaluation of serum antibiotic levels in a randomized, double-blind, placebo-controlled Department of Veterans Affairs Cooperative Study.

  1993cited by this paper
• PREVENTION OF Pneumocystis carinii PNEUMONIA IN CARDIAC TRANSPLANT RECIPIENTS BY TRIMETHOPRIM SULFAMETHOXAZOLE

  1993cited by this paper
• Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity

  1992cited by this paper
• Prospective randomized comparison of toxicity of two prophylactic regimens of cotrimoxazole in leukemic children.

  1992cited by this paper
• Trimethoprim-sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. A double-blind, randomized controlled trial.

  1992cited by this paper
• A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation. Side effects of trimethoprim-sulfamethoxazole, interaction with cyclosporine.

  1992cited by this paper
• TRIMETHOPRIM‐SULFAMETHOXAZOLE PROPHYLAXIS FOR PNEUMOCYSTIS CARINII INFECTIONS IN HEART‐LUNG AND LUNG TRANSPLANTATION—HOW EFFECTIVE AND FOR HOW LONG?

  1992cited by this paper
• Levamisole treatment in HIV-infected Zambian children.

  1992cited by this paper
• Co-trimoxazole versus dapsone-pyrimethamine for prevention of Pneumocystis carinii pneumonia.

  1992cited by this paper
• Effectiveness of low-dose contrimoxazole prophylaxis against Pneumocystis carinii pneumonia after renal and/or pancreas transplantation

  1992cited by this paper
• Low-dose co-trimoxazole, aerosolised pentamidine, or dapsone plus pyrimethamine for prevention of Pneumocystis carinii pneumonia.

  1991cited by this paper
• Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy

  1990cited by this paper
• A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis

  1990cited by this paper
• Prevention of infection in acute leukemia.

  1990cited by this paper
• Infection prophylaxis in neutropenic patients with acute leukaemia--a randomized, comparative study with ofloxacin, ciprofloxacin and co-trimoxazole/colistin.

  1990cited by this paper
• [Infection prophylaxis in patients with hematological malignancies (I)--Successful prophylaxis of Pneumocystis carinii pneumonitis with sulfamethoxazole-trimethoprim].

  1990cited by this paper
• Safety and Efficacy of Sulfamethoxazole and Trimethoprim Chemoprophylaxis for Pneumocystis carinii Pneumonia in AIDS

  1988cited by this paper
• Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS.

  1988cited by this paper
• Effect of trimethoprim/sulfamethoxazole prophylaxis on outcome of childhood lymphocytic leukemia a pediatric oncology group study

  1987cited by this paper
• Use of trimethoprim-sulfamethoxazole singly and in combination with other antibiotics in immunocompromised patients.

  1987cited by this paper
• Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis.

  1987cited by this paper
• Prospective randomized comparison of two prophylactic regimens with trimethoprim-sulfamethoxazole in leukemic children: a two year study.

  1987cited by this paper
• Use of trimethoprim‐sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia

  1985cited by this paper
• Prophylaxis of fever and infection in adult cancer patients. A placebo‐controlled trial of oral trimethoprim‐sulfamethoxazole plus erythromycin

  1984cited by this paper
• Trimethoprim/sulfamethoxazole versus placebo: a double-blind comparison of infection prophylaxis in patients with small cell carcinoma of the lung.

  1983cited by this paper
• Successful chemoprophylaxis for Pneumocystis carinii pneumonitis.

  1977cited by this paper
• Treatment of Pneumocystis carinii pneumonia: current status of the regimens of pentamidine isethionate and pyrimethamine-sulfadiazine.

  1976cited by this paper

• Multiple Myeloma Management in a Large Low- and Middle-Income Country: Lessons From India in Balancing Cost and Clinical Efficacy in Resource-Limited Settings.

  2026cites this paper
• Diagnostic Challenges and Modern Therapeutic Strategies in Giant Cell Arteritis

  2026cites this paper
• Microbiome-generated antifolates.

  2026cites this paper
• Post-COVID-19 severe Pneumocystis jirovecii pneumonia in a non-HIV and immunocompetent patient: A case report and literature review

  2025cites this paper
• Should Patients Receiving Induction for Lupus Nephritis Receive PJP Prophylaxis? An Opportunistic Discussion Between Nephrology and Rheumatology

  2025cites this paper
• Impact of the Duration of Trimethoprim–Sulfamethoxazole Prophylaxis on the Incidence of Infection After Kidney Transplantation: A Target Trial Emulation Study Within the Swiss Transplant Cohort Study (STCS)—The QUID‐PRO‐QUO Study (QUIDney Transplantation and Duration of PROphylaxis With QUO‐Trimoxaz

  2025cites this paper
• AIHA and rituximab: time for Pneumocystis prophylaxis?

  2025cites this paper
• Pneumocystis jiroveci Pneumonia Infections in Pediatric Solid Organ Transplant Recipients

  2025cites this paper
• Immune Checkpoint Inhibitor-Associated Cardiovascular Toxic Effects: International Cardio-Oncology Society Position Statement.

  2025cites this paper
• Translation into English and republication of: Pneumocystis jirovecii prophylaxis in non-HIV infected individuals: risk assessment and modalities.

  2025cites this paper
• Clinical analysis of Pneumocystis jirovecii pneumonia in children with malignant disease

  2025cites this paper
• Individualized Trimethoprim-Sulfamethoxazole Dosing in Non-HIV Patients with Pneumocystis Pneumonia: A Narrative Review of Current Evidence

  2025cites this paper
• Low-Dose Sulfamethoxazole-Trimethoprim Could Prevent Pneumocystis jiroveci Pneumonia in Kidney Transplant Recipients: A Retrospective, Observational Study

  2025cites this paper
• Pneumocystis jirovecii pneumonia with use of brentuximab vedotin in treatment-naïve Hodgkin lymphoma

  2025influential citation
• Investigation of the safety of Radium-223 chloride in combination with external beam radiotherapy for bone metastases of prostate cancer

  2025cites this paper
• Radiation Recall Pneumonitis with Pneumocystis jirovecii Superinfection and Treatment Induced Hyponatremia in a Patient with Non-Small-Cell Lung Cancer

  2025cites this paper
• Adjunctive corticosteroids in non-AIDS patients with severe Pneumocystis jirovecii pneumonia (PIC): a multicentre, double-blind, randomised controlled trial.

  2025cites this paper
• Duration of Pneumocystis Jirovecii Pneumonia Prophylaxis in Adult Kidney Transplant Recipients and Outcomes: A Population-Based Study.

  2025cites this paper
• Pneumocystis jirovecii pneumonia prophylaxis in patients with glioma receiving concurrent chemoradiation: a systematic review and meta-analysis

  2025cites this paper
• Flow Cytometry-based Immune Phenotyping of T and B Lymphocytes in the Evaluation of Immunodeficiency and Immune Dysregulation.

  2025cites this paper
• Consensus guidelines for patient and carer education on neutropenic fever

  2025cites this paper
• Risk of Pneumocystis Pneumonia in Patients With Rheumatoid Arthritis and the Role of Prophylactic Salazosulfapyridine

  2025cites this paper
• Combined multiplex polymerase chain reaction-based targeted next−generation sequencing and serum 1, 3-β-D-glucan for differential diagnosis of Pneumocystis pneumonia and Pneumocystis colonization

  2025cites this paper
• Clinical Factors Associated With Pneumocystis Pneumonia Despite Its Primary Prophylaxis: When to Stop Prophylaxis?

  2025cites this paper
• Twice Weekly Sulfamethoxazole/Trimethoprim for Pneumocystis jiroveci Pneumonia Prophylaxis in Lung Transplant Recipients

  2025cites this paper
• Clinician opinions on starting treatment for opportunistic infection prevention in interstitial lung disease: the STOP-ILD study

  2025cites this paper
• Pneumocystis jirovecii Pneumonia in Cancer Patients, a Lethal Yet Fully Preventable Disease: Insights From a Tertiary Cancer Center in East India

  2025cites this paper
• Evolving Risk Factors and Predisposing Conditions of Pneumocystis Pneumonia in Non-HIV Patients: A Seven-Year Multicenter Study.

  2025cites this paper
• Epidemiology, Clinical Characteristics, and Diagnostic Testing Practices for Pneumocystis Pneumonia-Associated Hospitalizations, United States, 2019-2022.

  2024cites this paper
• Chronic glucocorticoid management in neuromuscular disease: A survey of neuromuscular neurologists

  2024cites this paper
• Pneumocystis jirovecii pneumonia in people living with HIV: a review

  2024influential citation
• Antibiotic prophylaxis in immunosuppressed patients – Missed opportunities from trimethoprim-sulfamethoxazole allergy label

  2024cites this paper
• Flow Cytometry-based Immune Phenotyping of T and B Lymphocytes in the Evaluation of Immunodeficiency and Immune Dysregulation.

  2024cites this paper
• ICU-acquired infections in immunocompromised patients

  2024cites this paper
• Clinical Characteristics and Epidemiological Analysis of Pneumocystis Jirovecii Pneumonia Infection in Kidney Transplant Patients with Trimethoprim-Sulfamethoxazole Dose Reduction Prophylaxis Strategy

  2024cites this paper
• Infectious Disease Prophylaxis During and After Immunosuppressive Therapy

  2024cites this paper
• Pneumocystis Pneumonia in Locally Advanced Breast Cancer Despite Prophylactic Use of Trimethoprim-Sulfamethoxazole During Prednisolone Treatment for a Pembrolizumab-Induced Immune-Related Adverse Event: A Case Report

  2024cites this paper
• Deep mutational scanning of Pneumocystis jirovecii dihydrofolate reductase reveals allosteric mechanism of resistance to an antifolate

  2024cites this paper
• Clinical practice pattern of Pneumocystis pneumonia prophylaxis in systemic lupus erythematosus: a cross-sectional study from lupus registry of nationwide institutions (LUNA)

  2024cites this paper
• Risk of Invasive Fungal Infections in Patients With Chronic Lymphocytic Leukemia Treated With Bruton Tyrosine Kinase Inhibitors: A Case-Control Propensity Score–Matched Analysis

  2024influential citation
• Cutaneous Pneumocystis Jirovecii Infection in an Allogeneic Stem Cell Transplant Recipient

  2024cites this paper
• Efficacy and safety of a low-dose sulfamethoxazole/trimethoprim regimen in preventing pneumocystis pneumonia: A retrospective study using a large-scale electronic medical record database.

  2024cites this paper
• Prophylactic antibiotics and corticosteroid prescribing in palliative medicine: retrospective study

  2024cites this paper
• Treatment Effects in Randomized and Nonrandomized Studies of Pharmacological Interventions

  2024cites this paper
• Pneumocystis jirovecii Pneumonia Secondary to Blinatumomab Therapy: A Case Report

  2024cites this paper
• Intermittent Versus Daily Trimethoprim/Sulfamethoxazole Regimens for Pneumocystis Pneumonia Prophylaxis: A Systematic Review and Meta-analysis

  2024influential citation
• Management of infections for patient treated with ibrutinib in clinical practice

  2024cites this paper
• Investigating the WHO's AWaRe Classification for Assessing Antimicrobial Stewardship Programs: A Single-Center Study.

  2024cites this paper
• Profilaxia no Transplante Renal

  2024cites this paper
• In depth: The drug interaction between trimethoprim‐sulfamethoxazole and folic acid/folinic acid

  2024cites this paper
• Comment on “Pneumocystis jirovecii Pneumonia in Patients Treated for Solid Organ Malignancy”

  2024cites this paper
• Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2)

  2024cites this paper
• Prophylaxis in Kidney Transplantation

  2024cites this paper
• Pneumocystis jirovecii pneumonia in non-HIV patients: need for a more extended prophylaxis

  2024cites this paper
• Therapeutic Myths in Solid Organ Transplantation Infectious Diseases

  2024cites this paper
• Pneumocystis jirovecii Pneumonia in Patients Treated for Solid Organ Malignancy

  2024cites this paper
• The impact of continuity correction methods in Cochrane reviews with single‐zero trials with rare events: A meta‐epidemiological study

  2024cites this paper
• Epidemiology, Timing, and Secondary Prophylaxis of Recurrent Nocardiosis

  2024cites this paper
• A case of hypercalcemia from Pneumocystis jirovecii in an immunosuppressed non-HIV patient

  2024influential citation
• Variance in Pneumocystis jirovecii prophylaxis practice for pediatric patients undergoing hematopoietic cell transplantation

  2024cites this paper
• Interventions to reduce the risk of side-effects of cancer treatments in childhood

  2024cites this paper
• Glucocorticoid prescribing in neurology

  2024cites this paper
• Comparative Efficacy and Safety of Pneumocystis jirovecii Pneumonia Prophylaxis Regimens for People with HIV: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.

  2024cites this paper
• Strengths and limitations of molecular diagnostics for Pneumocystis jirovecii pneumonia

  2024cites this paper
• Clinical and Radiological Features of Pneumocystis jirovecii Pneumonia in Children: A Case Series

  2024cites this paper
• Perception of pneumocystis jirovecii pneumonia (PJP) prophylaxis in glioma patients receiving concurrent temozolomide and radiation– a patient and physician survey

  2024cites this paper
• Prophylaxis for Pneumocystis carinii pneumonia in non-Hodgkin’s lymphoma undergoing R-CHOP21 in China: a meta-analysis and cost-effectiveness analysis

  2023cites this paper
• Epidemiology, Risk Factors, and Prophylaxis Use for Pneumocystis jirovecii Pneumonia in the Non-HIV Population: A Retrospective Study in Québec, Canada

  2023cites this paper
• Pneumocystis jirovecii with high probability detected in bronchoalveolar lavage fluid of chemotherapy-related interstitial pneumonia in patients with lymphoma using metagenomic next-generation sequencing technology

  2023cites this paper
• Successful management of concurrent COVID-19 and Pneumocystis Jirovecii Pneumonia in kidney transplant recipients: a case series

  2023cites this paper
• Die Rolle von Pneumocystis jirovecii Infektionen bei Rheuma-Patienten

  2023cites this paper
• Dismal prognosis of Pneumocystis jirovecii pneumonia in patients with multiple myeloma

  2023cites this paper
• Pneumocystis jirovecii pneumonia mortality risk associated with preceding long-term steroid use for the underlying disease: A multicenter, retrospective cohort study

  2023cites this paper
• Assessment of the Prevalence of Infections in Pediatric Patients With Acute Lymphoblastic Leukemia

  2023cites this paper
• Case Report: Comprehensive Management of Pneumocystis Jiroveci Pneumonia (PJP) and Secondary Infections of Multiple-Drug Resistant Enterobacter cloacae complex and Pseudomonas aeruginosa in a Kidney Transplant Recipient with Sulfonamide Allergies

  2023cites this paper
• Prophylaxis Against Pneumocystis Pneumonia.

  2023cites this paper
• Prevention, Diagnosis and Management of Pneumocystis jirovecii Infection in Children With Cancer or Receiving Hematopoietic Cell Therapy.

  2023cites this paper
• Clinical performance of BALF droplet digital PCR for differential diagnosis of Pneumocystis jirovecii pneumonia and Pneumocystis jirovecii colonization.

  2023cites this paper
• Cotrimoxazole as a Preventative Intervention for Pneumocystis Pneumonia in Pemphigus Patients Treated with Rituximab: A Retrospective Study

  2023influential citation
• Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA‐Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide

  2023cites this paper
• A single-center, person-month-based analysis of the risk of developing Pneumocystis pneumonia (PCP) in immunosuppressed non-HIV patients: Preventive effects of trimethoprim-sulfamethoxazole.

  2023cites this paper
• Molecular and microscopy detection of Pneumocystis jirovecii in hospitalized patients during the COVID-19 pandemic

  2023cites this paper
• First-line immunosuppression in neuromuscular diseases

  2023cites this paper
• Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.1) – Februar 2023 – AWMF-Registriernummer: 021-009

  2023cites this paper
• Antifungal prophylaxis and pre-emptive therapy: When and how?

  2023cites this paper
• Pneumocystis jiroveci Pneumonia: A Review of Management in Human Immunodeficiency Virus (HIV) and Non-HIV Immunocompromised Patients

  2023cites this paper
• Incidence of Pneumocystis Pneumonia in Immunocompromised Patients without Human Immunodeficiency Virus on Intravenous Pentamidine Prophylaxis: A Systematic Review and Meta-Analysis

  2023cites this paper
• Prescribed daily-dose–based metrics of oral antibiotic use for hospitalized children in Japan

  2023cites this paper
• Effects of antibiotics ceftriaxone and levofloxacin on the growth of Lucilia sericata (Diptera: Calliphoridae)

  2023cites this paper
• Rising Incidence of Pneumocystis pneumonia: a population-level descriptive ecological study in England.

  2023cites this paper
• Supportive interventions for childhood cancer: An umbrella review of randomized evidence.

  2022cites this paper
• Clinical characteristics of and risk factors for Pneumocystis jirovecii pneumonia in anti-melanoma differentiation-associated gene 5 (Anti-MDA5) antibody-positive dermatomyositis patients: a single-center retrospective study

  2022cites this paper
• Management of community acquired pneumonia (CAP) in children: Clinical practice guidelines by the Paediatric Association of Nigeria (PAN)

  2022cites this paper
• Is there a role for Pneumocystis jiroveci pneumonia prophylaxis in giant cell arteritis or polymyalgia rheumatica?

  2022cites this paper
• Methemoglobinemia in a 28-year-old woman treated with dapsone

  2022cites this paper
• Pneumocystis jirovecii pneumonia [PJP]: An unrecognized concern in AML patients on Venetoclax.

  2022cites this paper
• Population kinetic–pharmacodynamic analysis of serum potassium in patients receiving sulfamethoxazole/trimethoprim

  2022cites this paper
• Pneumocystis pneumonia with respiratory failure in a HIV-negative patient following short course of low-dose to moderate-dose prednisolone for a dermatological condition

  2022cites this paper
• Pneumocystis jiroveci pneumonia prophylaxis in patients with autoimmune hepatitis

  2022cites this paper
• Clinical Value of Metagenomic Next-Generation Sequencing in Immunocompromised Patients with Sepsis

  2022cites this paper